Added to YB: 2026-01-21
Pitch date: 2026-01-19
SLS [neutral]
SELLAS Life Sciences Group, Inc.
+3.59%
current return
Author Info
No bio for this author
Company Info
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States.
Market Cap
$677.7M
Pitch Price
$3.90
Price Target
N/A
Dividend
N/A
EV/EBITDA
-23.11
P/E
-14.15
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
$SLS REGAL's flawed assumptions
SLS (sell): REGAL Phase 3 GPS vaccine trial's 'positive' delay in deaths likely reflects control arm baseline survival severely underestimated at 8mo vs reality. Trial enriched for fit patients getting 1st-time Venetoclax+HMA creates 'super responder' control (NPM1/IDH mutations) potentially surviving 12mo+, making statistical significance vs GPS nearly impossible.
Read full article (5 min)